1887
Letter Open Access
Like 0
This item has no PDF Download

There is no abstract available for this article.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.11.30483
2017-03-16
2017-10-20
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.11.30483
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/11/eurosurv-22-30483-5.html?itemId=/content/10.2807/1560-7917.ES.2017.22.11.30483&mimeType=html&fmt=ahah

References

  1. Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C, et al. National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. Euro Surveill. 2017;22(2):30436.  https://doi.org/10.2807/1560-7917.ES.2017.22.2.30436  PMID: 28105988 
  2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.  https://doi.org/10.1056/NEJMoa1011205  PMID: 21091279 
  3. European Centre for Disease Prevention and Control (ECDC). Pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/pre-exposure-prophylaxis-hiv-prevention-europe.pdf
  4. Ross EL, Cinti SK, Hutton DW. Implementation and operational research: a cost-effective, clinically actionable strategy for targeting HIV preexposure prophylaxis to high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2016;72(3):e61-7.  https://doi.org/10.1097/QAI.0000000000000987  PMID: 26977749 
  5. Nichols BE, Boucher CA, van der Valk M, Rijnders BJ, van de Vijver DA. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016;16(12):1423-9.  https://doi.org/10.1016/S1473-3099(16)30311-5  PMID: 27665989 
  6. van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis. 2010;23(6):621-7.  https://doi.org/10.1097/QCO.0b013e32833ff1e6  PMID: 20847692 
  7. Knox DC, Tan DH, Harrigan PR, Anderson PL. HIV-1 Infection with multiclass resistance despite preexposure prophylaxis (PrEP). Conference on Retroviruses and Opportunistic Infections (CROI); 22-25 Feb 2016; Boston. Available from: http://www.croiconference.org/sessions/hiv-1-infection-multiclass-resistance-despite-preexposure-prophylaxis-prep
  8. Grossman H. Newly acquired HIV-1 infection with multi-drug resistant (MDR) HIV-1 in a patient on TDF/FTC-based PrEP. Research for Prevention; 17-21 Oct 2016; Chicago.
  9. European Society for translational Antiviral Research (ESAR). SPREAD Surveillance Program. Utrecht: ESAR. [Accessed: 2 Mar 2017]. Available from: http://www.esar-society.eu/spread-surveillance-program
  10. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. SPREAD Program. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62(5):655-63.  https://doi.org/10.1093/cid/civ963  PMID: 26620652 
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error